Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Acquired by Quest Partners LLC

Quest Partners LLC boosted its position in Sage Therapeutics, Inc. (NASDAQ:SAGEFree Report) by 56.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,381 shares of the biopharmaceutical company’s stock after acquiring an additional 6,618 shares during the quarter. Quest Partners LLC’s holdings in Sage Therapeutics were worth $133,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Headlands Technologies LLC lifted its position in shares of Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,782 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 4,672 shares during the last quarter. Creative Planning acquired a new position in shares of Sage Therapeutics during the 3rd quarter worth about $88,000. Lazard Asset Management LLC purchased a new position in shares of Sage Therapeutics in the 1st quarter valued at about $127,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Sage Therapeutics during the 2nd quarter worth about $153,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Performance

NASDAQ:SAGE opened at $5.55 on Friday. The company has a market capitalization of $339.49 million, a price-to-earnings ratio of -0.99 and a beta of 0.92. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $28.26. The stock has a 50-day simple moving average of $6.58 and a 200 day simple moving average of $8.88.

Sage Therapeutics (NASDAQ:SAGEGet Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company’s quarterly revenue was up 337.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.81) earnings per share. On average, equities research analysts forecast that Sage Therapeutics, Inc. will post -6.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SAGE shares. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price on the stock in a research report on Thursday, November 21st. Oppenheimer decreased their target price on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 6th. Piper Sandler reiterated an “overweight” rating and issued a $26.00 price objective (down previously from $52.00) on shares of Sage Therapeutics in a research note on Wednesday, October 30th. Finally, Raymond James restated a “market perform” rating on shares of Sage Therapeutics in a research report on Thursday, October 10th. Three equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $12.83.

Check Out Our Latest Stock Analysis on Sage Therapeutics

About Sage Therapeutics

(Free Report)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.

Featured Articles

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGEFree Report).

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.